Eye implant offers new hope

Article

A new implant that allows patients suffering from advanced age-related macular degeneration (AMD) to improve their general vision and regain independence is now being implanted in the UK.

A new implant that allows patients suffering from advanced age-related macular degeneration (AMD) to improve their general vision and regain independence is now being implanted in the UK.

The CentraSight treatment programme features a small telescope implant for patients with binocular end stage AMD. This treatment has, until now, only been available in the US and is the only surgical option that has been clinically proven to improve visual quality and quality in life for patients at this stage of the disease.

Mr Ahmed El-Amir, consultant ophthalmologist at Spire Dunedin, Reading, UK, was the first surgeon to perform the procedure in the UK. “I am very pleased to be able to offer my patients this revolutionary treatment, which is a true paradigm shift for patients with untreatable, advanced AMD who have had, up to now, very limited options in improving their quality of life,” he said.

Another surgeon who has recently performed a CentraSight procedure, Mr Nick Wilson-Holt (Duchy Hospital, Truro, UK) added, “CentraSight is a clinical programme that is very carefully targeted only to suitable patients who will potentially gain visual acuity from the procedure. It is not a cure for end-stage AMD, but it allows patients to use the undamaged part of their central retina to be able to see or discern objects using portions of their central vision once more.”

More detailed information about the procedure and its availability may be found on the website.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.